Numerous studies have indicated that a modified proteinase K-resistant form of an endogenous brain protein, prion protein (PrP), is associated with scrapie infection in animals. This scrapie-associated PrP modification appears to occur posttranslationally in brain, but its molecular nature is not known. To learn about the normal PrP biosynthesis and whether it is altered by scrapie infection in vitro, we did metabolic labeling experiments with uninfected and scrapie-infected mouse neuroblastoma tissue culture cells. Pulsechase labeling experiments indicated that, in both cell types, two major PrP precursors of 28 and 33 kilodaltons (kDa) were processed to mature 30-and 35-to 41-kDa forms. Endoglycosidase H, tunicamycin, and phospholipase treatments revealed that the 28-and 33-kDa precursors resulted from the addition of high-mannose glycans to a 25-kDa polypeptide containing a phosphatidylinositol moiety and that maturation of the precursors involved the conversion of the high-mannose glycans to hybrid or complex glycans. Treatments of the live cells with trypsin and phosphatidylinositol-specific phospholipase C indicated that the mature PrP species were expressed solely on the cell surface, where they were anchored by covalent linkage to phosphatidylinositol. Once on the cell surface, the major PrP forms had half-lives of 3 to 6 h. No differences in PrP biosynthesis were observed between the scrapie-infected versus uninfected neuroblastoma cells.
The causative agents of scrapie, kuru, Creutzfeldt-Jakob disease, and related transmissible degenerative neuropathies of mammals have not been conclusively identified. These agents appear highly resistant to treatments harmful to nucleic acids (1, 3, 12, 21, 32) , and no agent-specific nucleic acids have been identified. Therefore, it was postulated that the infectious agents are devoid of genetic material and composed primarily of protein (1, 15, 30, 32) . However, since the agents are also highly resistant to proteases under most conditions (25, 26) , it has been difficult to draw accurate conclusions about their composition.
Attempts to purify the scrapie agent from brain led to the discovery of a particular protein, named prion protein (PrP) (5, 26, 33) or scrapie-associated fibril protein (13) , as the major protein component of fractions containing scrapie infectivity. It was proposed that this protein, or an aggregate thereof, is the scrapie infectious agent (5, 13, 27) . However, recent studies have shown that PrP is a normal endogenous protein of brain and a variety of other tissues (8, 10, 11, 18, 28, 29, 36) . Scrapie infection does not appear to modify the endogenous PrP gene of brain (2) or the size and quantity of PrP mRNA (10, 29) . Furthermore, expression of the PrP gene cloned from scrapie-infected mouse brain was not sufficient to cause the synthesis of the scrapie agent in mouse tissue culture cells (9) . However, the disease results in the accumulation of a proteinase K-resistant form of PrP in brain which can aggregate into fibrils (11, 13, 18, 26, 28, 36) . The chemical basis for the resistance to proteinase K is not known. Since no alteration of the mRNA encoding PrP has been detected, it would appear that the acquisition of proteinase K resistance is posttranslational. However, although several posttranslational modifications of PrP in hamster * Corresponding author.
brain are known to occur (6, 16, 24, 37) , none have been found to be scrapie specific. It is possible that proteinase K resistance does not require covalent modification but instead requires aggregation, conformational change, or association of the endogenous PrP with other components of scrapieinfected tissues. Whether a proteinase K-resistant form of PrP is the infectious scrapie agent itself, a component of the agent, or merely a secondary by-product of the disease in vivo remains to be determined.
To provide a system in which PrP and the scrapie agent can be studied in the absence of in vivo tissue pathology, we recently developed scrapie-infected mouse neuroblastoma cell clones with a high percentage of infected cells (34) . In preliminary studies, we found that the mature PrP detected in the infected cells was neither resistant to proteinase K nor altered in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) mobility by the presence of the scrapie agent. These results suggested that the scrapie agent is replicated in vitro in the absence of proteinase K-resistant PrP. However, it is also possible that scrapie infection is directly associated with biochemical alterations in normal PrP structure which might not result in resistance to proteinase K under tissue culture conditions. To learn more about PrP biosynthesis and whether scrapie infection alters the process in vitro, we extended our studies of these neuroblastoma cells. Here we identified the biosynthetic precursors of PrP in both scrapie-infected and uninfected neuroblastoma cells and monitored their maturation and transport to the cell surface.
MATERIALS AND METHODS
Neuroblastoma cells. The scrapie-infected (sc+) neuroblastoma cell clone 29-161, the scrapie-negative (sc-) clone , and the normal uncloned neuroblastoma cells used in this study have been described previously (34, 35 were glycosylated and, if so, to identify the unglycosylated precursor of PrP biosynthesis, we labeled neuroblastoma cells in the presence of tunicamycin, a drug which prevents lipid carrier-dependent N-glycosylation of proteins (14) . In the sc+ and sc-clones, tunicamycin reduced the synthesis of 30-and 35-to 41-kDa PrPs and greatly increased the label in the 25-kDa band, which was a minor component of PrP in control cells (Fig. 2) . Tunicamycin did not influence the labeling of the nonspecific background proteins, indicating that the observed effects were due to the specific inhibition of glycosylation and not protein synthesis generally. Thus, the 25-kDa band was likely the PrP polypeptide lacking N-linked carbohydrate, though it remains possible that 0-linked carbohydrate was attached. When normal uncloned neuroblastoma cells were treated identically with tunicamycin labeling was increased in both the 25-and 26-kDa PrP bands observed in the pulse-chase study described above.
Endoglycosidase treatments. To help identify the multiple glycosylated forms of PrP observed in the pulse-chase studies, we treated denatured PrP immunoprecipitates with endoglycosidase H (Fig. 3) , which removes high-mannose glycans from glycoproteins (38) . Endoglycosidase H treatment of the PrP precursors of both the sc+ and sc-clones labeled for 7 min resulted in the conversion of 28-and 33-kDa PrP bands to a band of -26 kDa. This provided evidence that the larger two bands were the PrP polypeptide with differing amounts of high-mannose glycan attached. Upon further processing of PrP, it was apparent that the high-mannose glycans were replaced with complex glycans since the mature forms labeled in the 2-h period were not altered by endoglycosidase H. Since there are two potential N-glycosylation sites in the mouse PrP sequence (22) , the difference between the 28-and 33-kDa precursors could have been the glycosylation of one versus both sites, respectively. The presence of a residual N-acetylglucosamine residue normally left by the enzyme at one or both of the potential glycosylation sites may account for the deglycosylated PrP appearing slightly larger than 25 kDa. No differences between the sc+ and sc-clones were observed.
Transport of PrP to the cell surface. In a previous study, we found that PrP detected on the cell surface by immunofluorescence could be removed with trypsin and thus that PrP was an exofacial plasma membrane protein (9) . To determine which of the forms of PrP were transported to the cell surface, sc+ neuroblastoma cells labeled for 15 min or 3 h were treated with trypsin before lysis (Fig. 4) . The PrP precursors labeled in the short pulse were protected from extracellular trypsin, which was consistent with their being associated with the endoplasmic reticulum or Golgi apparatus or both. On the other hand, the 30-and 35-to 41-kDa PrP bands' labeled in 3 h were all digested and thus were expressed on the cell surface as final products of PrP biosynthesis. Trypsin treatments of sc+ cells pulse-chase labeled as described in the legend to Fig. 2 (23) . To determine whether the same is true of PrP biosynthesis, we treated the early PrP precursors with PIPLC after immunoprecipitation (Fig. 6) . As was the case for the mature forms of PrP on the cell surface, the electrophoretic mobilities of the 25-, 28-, and 33-kDa precursors decreased with PIPLC treatment. This indicated that early PrP precursors contained phosphatidylinositol and, therefore, that the addition of the phospholipid anchor occurred before or concurrent with high-mannose glycan addition.
Release of PrP from cells. Previous studies have indicated that PrP may be targeted both as a plasma membrane protein and as a secretory protein (9, 17) . To test whether a proportion of pulse-labeled PrP was released from normal neuroblastoma cells and the sc+ and sc-clones, we immunoprecipitated PrP from the cell lysate and the chase medium. By scanning densitometry of fluorograms, it was estimated that a maximum of 3 to 10% of the labeled 35-to 41-kDa PrP was lost from the cells and was detected in the medium following chases of 4 and 16 h, the latter being long enough to effectively eliminate labeled PrP from the cells (data not shown). This suggested that catabolism, not secretion or release from the cell surface, was the major fate of PrP lost from these cells. (Fig. 7) . Since mouse PrP has a hydrophobic amino-terminal signal sequence (22) and is targeted as a plasma membrane protein, its biosynthetic processing presumably begins within the endoplasmic reticulum. The earliest PrP precursors detected in the sc-and sc+ neuroblastoma clones are the 25-kDa PrP polypeptide with phosphatidylinositol and its 28-and 33-kDa derivatives carrying differing amounts of high-mannose glycan. The simultaneous labeling of these three forms of PrP is consistent with studies of other proteins showing that the addition of glycosyl-phosphatidylinositol (23) and high-mannose glycans (20) can occur concurrent with or soon after translation and translocation of polypeptides into the lumen of the endoplasmic reticulum. Since the 25-kDa PrP appears smaller in molecular size than the theoretical value of 27.8 kDa calculated for the full-length PrP polypeptide (22) , the nascent PrP polypeptide may be rapidly truncated in the endoplasmic reticulum. This truncation may result from the removal of an amino-terminal signal peptide by signal peptidase, as has been shown to occur with hamster PrP in brain (4, 18) . Also, a carboxy-terminal peptide sequence may be removed prior to the addition of phosphatidylinositol, as described for two other proteins containing glycosyl-phosphatidylinositol groups (23) .
Within the next 10 to 30 min, the high-mannose glycans on the 28-and 33-kDa PrPs are processed to yield complex or hybrid glycans, presumably during passage through the Golgi apparatus (31) . At Since the 25-kDa PrP arrives at the cell surface, albeit at a slower rate than 30-and 35-to 41-kDa PrPs, N-linked glycosylation must not be essential for the proper trafficking through the intracellular biosynthetic apparatus. This is also the case for several other plasma membrane and secreted proteins (14) . The reason for the smallest PrP having a slower rate of transport to the plasma membrane is unknown. However, studies of the constitutive transport of other proteins to the plasma membrane have indicated that the rate-limiting step is export from the endoplasmic reticulum (14, 31) . Furthermore, an important prerequisite for this step appears to be the proper folding of nascent polypeptide chains and/or their assembly into oligomers (31) . Thus, the addition of N-linked high-mannose sugars to the nascent PrP polypeptide may facilitate the preparation of PrP for export from the endoplasmic reticulum.
Comparison of scrapie-infected and uninfected neuroblastoma cells. The sequence of events in PrP biosynthesis outlined above occurred in both scrapie-infected and uninfected neuroblastoma cells. Thus, we have no evidence that scrapie infection modifies PrP biosynthesis in these cells. It remains conceivable that subtle scrapie-specific modifications of the oligosaccharide structure or other posttranslational modifications could have occurred without being detected by the techniques used. Another possibility is that scrapie infection results in the modification of a small proportion of the total PrP below the level of detection. This would be consistent with our previous study showing that none of the PrP detected in this sc+ neuroblastoma clone had the proteinase K resistance typical of most of the PrP extracted from the brains of scrapie-infected animals (34) . However, an alternative explanation might be that a modified form of PrP is not a necessary component of the infectious scrapie agent but arises as a pathological byproduct of the disease in vivo (7) under conditions which were not duplicated in tissue culture.
Comparison of live-cell biosynthesis to cell-free translation. In studies of the synthesis of hamster PrP in cell-free translation systems containing microsomal membranes, PrP species of 25, 28 , and 33 kDa were observed (16 
